Schering-Plough Appoints Janet M. Barth Vice President, Investor Relations

Wednesday, May 28, 2008 General News J E 4
KENILWORTH, N.J., May 27 Schering-PloughCorporation (NYSE: SGP) today announced that Janet M. Barth has been appointedvice president, investor relations, effective immediately.

In this role, Barth will be responsible for developing, implementing andcontinually improving a comprehensive global investor relations program forSchering-Plough. She will lead the formulation and execution of external andinternal investor communications plans to support Schering-Plough's businessobjectives. She also will partner with the company's senior management teamon matters pertaining to the investment community and individual shareholders.

Barth reports to Alex Kelly, group vice president, global communicationsand investor relations. She assumes the investor relations responsibilitiesthat were previously fulfilled by Kelly, who was named to his current expandedrole in October 2007.

Barth most recently served as senior vice president, investor relationsand corporate communications, for Adams Respiratory Therapeutics, which was anewly public specialty pharmaceutical company. In that role, she established,developed and directed comprehensive investor relations and corporatecommunications programs for the company prior to its acquisition by ReckittBenckiser in January 2008.

Previously, Barth was employed for 14 years by Schering-Plough, where sheheld various positions of increasing responsibility, including that ofdirector, investor relations. Barth holds a Bachelor of Arts degree in policyand management studies from Dickinson College, Carlisle, Pa., and a Master ofBusiness Administration degree from Seton Hall University, South Orange, N.J.She joined the National Investor Relations Institute (NIRI) in 1996 andcurrently is a member of NIRI's New York and Virtual Chapters. Barth completeda 12-month leadership development program with Women Unlimited LEAD(Leadership Education and Development) in 2005.

Schering-Plough is an innovation-driven, science-centered global healthcare company. Through its own biopharmaceutical research and collaborationswith partners, Schering-Plough creates therapies that help save and improvelives around the world. The company applies its research-and-developmentplatform to human prescription and consumer products as well as to animalhealth products. Schering-Plough's vision is to "Earn Trust, Every Day" withthe doctors, patients, customers and other stakeholders served by itscolleagues around the world. The company is based in Kenilworth, N.J., and itsWeb site is

SOURCE Schering-Plough Corporation


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Node-Negative Early Stage Breast Cancer Patients B...
Verity Radiation Therapy Becomes Second U.S. Medic...